| dc.description.sponsorship | Tim Spelman received compensation for serving on scientific advisory boards, honoraria for consultancy and funding for travel from Biogen Inc and speaker honoraria from Novartis.; Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck-Serono, Teva, Novartis and Almirall; has received research grants for her institution from Biogen-Idec, Merck Serono and Novartis.; Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi and Teva, research grants from the Associazione Italiana Sclerosi Multipla.; Pierre Grammond is a Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck Serono, received payments for lectures by Merck Serono, Teva-neuroscience and Canadian Multiple Sclerosis Society, and received grants for travel from Teva-neuroscience and Novartis.; Patrizia Sola received travel grants and speaking honoraria from Bayer Schering, Biogen, Merck Serono, Novartis, Sanofi/Genzyme and Teva.; Diana Ferraro received travel grants and/or speaker honoraria from Merck Serono, Biogen, TEVA, Novartis, Sanofi-Genzyme.; Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals.; Murat Terzi received travel grants from Merck Serono, Novartis, Bayer Schering and Teva and has participated in clinical trials by Sanofi-Aventis, Roche and Novartis.; Raymond Hupperts received honoraria as consultant on scientific advisory boards from Merck-Serono, Biogen, Genzyme-Sanofi and Teva, research funding from Merck-Serono and Biogen, and speaker honoraria from Sanofi-Genzyme and Novartis.; Jeannette Lechner-Scott has accepted travel compensation from Novartis, Biogen and Merck Serono. Her institution receives the honoraria for talks and advisory board commitment and also clinic support from Bayer Health Care, Biogen, CSL, Genzyme Sanofi, Merck Serono and Novartis.; Ludwig Kappos's institution (University Hospital, Basel) received in the last 3 years and used exclusively for research support: steering committee, advisory board and consultancy fees from Actelion, Addex, Bayer HealthCare, Biogen, Biotica, Genzyme, Lilly, Merck, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptos, Sanofi-Aventis, Santhera, Siemens, Teva, UCB and Xenoport; speaker fees from Bayer HealthCare, Biogen, Merck, Novartis, Sanofi-Aventis and Teva; support of educational activities from Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck, Novartis, Sanofi-Aventis and Teva; royalties from Neurostatus Systems GmbH; and grants from Bayer HealthCare, Biogen, the European Union, Merck, Novartis, Roche, Roche Research Foundations, Swiss MS Society and the Swiss National Research Foundation.; Eugenio Pucci served on scientific advisory boards for Genzyme and Biogen; he has received honoraria and travel grants from Sanofi Aventis, UCB, Lundbeck, Novartis, Bayer Schering, Biogen, Merck Serono, Genzyme and Teva; he has received travel grants from Associazone Marchigana Sclerosi Multipla e altre malattie neurologiche.; Suzanne Hodgkinson received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering.; Claudio Solaro served as a member of the advisory board of the following companies: Biogen Idec and Merck Serono; received speaking honoraria from Bayer Schering, Biogen Idec, Merck Serono, Teva, Almirall, and Sanofi Genzyme and research grants and support by the FISM (Fondazione Italiana Sclerosi Multipla); Helmut Butzkueven served on scientific advisory boards for Biogen, Novartis and Sanofi-Aventis and has received conference travel support from Novartis, Biogen and Sanofi Aventis. He serves on steering committes for trials conducted by Biogen and Novartis, and has received research support from Merck Serono, Novartis and Biogen. | en_US |
